Oncol Res Treat. 2023 Oct 19. doi: 10.1159/000534674. Online ahead of print.
ABSTRACT
INTRODUCTION: Owing to its low incidence, there no reliable statistics about prognostication derived from large sample sizes have been reported of malignant ovarian germ cell tumors (MOGCTs) and sex cord-stromal tumors (SCSTs). The present study aimed to investigate the clinicopathological prognostic factors and the survival trends of MOGCTs and SCSTs.
MATERIALS AND METHODS: Patients with MOGCTs and SCSTs were recorded in the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2000 and 2019. Clinical, demographic, and treatment characteristics were compared between groups of MOGCTs and SCSTs. Cox risk regression analysis and Kaplan-Meier survival curves were used to compare overall survival (OS) and cancer-specific survival (CSS), and to assess the prognostic factors.
RESULTS: Information of 2506 patients with MOGCTs and 1556 patients with SCSTs was extracted from the SEER database, respectively. Aged <40 years and single were more common in patients with MOGCTs than in those with SCSTs. The vast majority of patients with MOGCTs and SCSTs underwent surgery (98.1% vs. 94.5%; P<0.001) and women with MOGCTs were more likely to receive chemotherapy than women with SCSTs (56.1% vs. 32.2%; P<0.001). For both patients before and after propensity-score matching, the 5-year OS rates of patients with SCSTs were lower than that of patients with MOGCTs (P<0.05). In multivariate Cox regression analysis, both age and surgery were independent predictors of OS in patients with MOGCTs and SCSTs. FIGO staging was an independent predictor of CSS in MOGCT patients. Tumor size and chemotherapy were also independent predictors of CSS in patients with SCSTs.
CONCLUSION: Compared to patients with SCSTs, those with MOGCTs tended to be younger and had a higher OS and CSS. Adjuvant chemotherapy after surgery did not prolong OS and CSS in patients with SCSTs.
PMID:37857263 | DOI:10.1159/000534674
